Journal of Behavioral and Brain Science
2023
Melissa C. Selinger, David M. Compton, Hamilton Morris et al.
3 citations
The management of patients with concomitant chronic pain (CP) and Major Depressive Disorder (MDD) remains challenging for clinicians. Current chronic pharmacologic management is often unsuccessful, or has intolerable side effects to the patients. While not restricted to patients with chronic pain, these patients are often diagnosed with depression, presenting with symptoms such as poor mood,...
December 1, 2012
D. Compton, Melissa C. Selinger, E. Westman et al.
Fo xy or Methoxy Fo xy (5-MeO-DIPT) is one of a series of new "club drugs" that within the past decade has gained in popularity among recreational users as an alternative to MDMA (Ecstasy). Unlike M DMA, not much is known about the neurobiological consequences of 5-MeO-DIPT use. Little is known about the effects of either co mpound on learning in a nonspatial appetitive task. In the present...
Physiology & Behavior
May 3, 2011
David M. Compton, Kerri L. Dietrich, Melissa C. Selinger et al.
21 citations
Foxy or Methoxy Foxy (5-methoxy-N,N-di(iso)propyltryptamine hydrochloride; 5-MeO-DIPT) is rapidly gaining popularity among recreational users as a hallucinogenic "designer drug." Unfortunately, much remain unknown about the consequences of its use on neuropsychological development or behavior. During one of two adolescent periods, the rats were given repeated injections of 5 mg/kg or 20 mg/kg...
Psychological Reports
June 1, 2006
David M. Compton, Melissa C. Selinger, Erin K Testa et al.
16 citations
The hallucinogenic "designer drug" known as Foxy or Methoxy Foxy and formally know as 5-Methoxy-N,N-di(iso)propyltryptamine hydrochloride (5-MeO-DIPT) is rapidly gaining popularity among recreational users. However, little is known about the consequences of its use on neuropsychological development or behavior. During one of two adolescent periods, the rats were given repeated injections of...